Tuesday, October 27, 2026

HBM's 3x Wafer Cost Keeps Global AI Memory Prices Elevated Through 2027

Three companies — South Korea's SK hynix and Samsung, and US-based Micron — control virtually all high-bandwidth memory supply while global AI demand is forecast to grow 35x by 2028. DRAM contract prices are projected to rise 58–63% in Q2 2026 alone, with Gartner forecasting a 125% full-year increase. A structural manufacturing constraint, not market timing, is driving the shortage.

LM Salvado
LM Salvado

May 12, 2026

HBM's 3x Wafer Cost Keeps Global AI Memory Prices Elevated Through 2027
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Three manufacturers — South Korea's SK hynix, Samsung, and US-based Micron — control virtually all HBM supply. Each gigabyte of HBM requires three times the wafer capacity of standard DRAM.1 That physics-driven constraint is why no production ramp resolves the shortage quickly.

DRAM contract prices are forecast to rise 58–63% in Q2 2026 alone.1 Gartner projects a 125% full-year DRAM price increase for 2026.2 Both SK hynix and Samsung warn the shortage will persist through at least end of 2027.1

Demand is accelerating from every direction simultaneously. Counterpoint Research forecasts HBM demand from custom AI processors will grow 35x between 2024 and 2028.3 US hyperscalers, Chinese cloud giants, and European AI infrastructure builders are all competing for the same constrained wafer output.

HBM stacks multiple DRAM dies vertically using through-silicon vias (TSVs), delivering the wide memory bandwidth that large language models require. That stacking process demands more wafer area per unit of storage — a manufacturing reality that limits gigabyte output even as fab capacity expands.

Micron's stock has surged 162% year-to-date in 2026.1 Markets are pricing in a sustained premium, not a temporary spike. The company's Singapore facility is on a production ramp timeline targeting H2 2028.1 Until new capacity comes online across all three suppliers, supply growth remains structurally capped.

For AI infrastructure builders worldwide, the bottleneck is direct. HBM bandwidth determines model serving throughput. Constrained HBM supply means constrained AI inference capacity — regardless of GPU production volumes anywhere in the world.

The mismatch between 35x projected demand growth and supply expansion measured in single-digit percentages annually defines the structural case for elevated pricing through 2027.3 Wafer area is finite. HBM's manufacturing requirements are not shrinking. Until Micron's Singapore lines and expanded Korean fab capacity reach production scale, the constraint holds globally.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com